Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 2Conjunctival Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × Ranibizumab × Clear all
NCT00456495 2017-07-21

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

The New York Eye Cancer Center

Phase 1 Completed
5 enrolled 6 charts

Conjunctival Neoplasms

NCT00680225 2017-04-12

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

New England Retina Associates

Phase 3 Completed
10 enrolled 4 charts
Dermatologic

Uveal Melanoma

NCT01251978 2016-10-19

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New England Retina Associates

Phase 2 Completed
10 enrolled 7 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡